Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Burning Rock Reports Third Quarter 2025 Financial Results
-
Burning Rock's OncoGuide™ OncoScreen™ Plus CDx System Now Approved in Japan as a Companion Diagnostic for Capivasertib in Breast Cancer
-
Burning Rock Reports Second Quarter 2025 Financial Results
-
Burning Rock Reports First Quarter 2025 Financial Results
-
Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results
-
Burning Rock Announces Results of 2024 Annual General Meeting
-
Burning Rock Reports Third Quarter 2024 Financial Results
-
Burning Rock Announces 2024 Annual General Meeting to be Held on December 31, 2024
-
NMPA Grants Marketing Approval to the First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer in China
-
GUANGZHOU, China, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR) (the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing...